456 related articles for article (PubMed ID: 29080382)
1. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
2. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
[TBL] [Abstract][Full Text] [Related]
3. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
He S; Blombäck M; Jacobsson Ekman G; Hedner U
J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
[TBL] [Abstract][Full Text] [Related]
4. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.
Rea CJ; Foley JH; Ingerslev J; Sørensen B
J Thromb Haemost; 2011 Mar; 9(3):510-6. PubMed ID: 21155966
[TBL] [Abstract][Full Text] [Related]
5. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
6. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.
Byrnes JR; Duval C; Wang Y; Hansen CE; Ahn B; Mooberry MJ; Clark MA; Johnsen JM; Lord ST; Lam WA; Meijers JC; Ni H; Ariëns RA; Wolberg AS
Blood; 2015 Oct; 126(16):1940-8. PubMed ID: 26324704
[TBL] [Abstract][Full Text] [Related]
7. FXIII: mechanisms of action in the treatment of hemophilia A.
Rea CJ; Foley JH; Okaisabor O; Sørensen B
J Thromb Haemost; 2014 Feb; 12(2):159-68. PubMed ID: 24354581
[TBL] [Abstract][Full Text] [Related]
8. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Pitkänen HH; Jouppila A; Lemponen M; Ilmakunnas M; Ahonen J; Lassila R
Thromb Res; 2017 Jan; 149():56-61. PubMed ID: 27902939
[TBL] [Abstract][Full Text] [Related]
9. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
Sørensen B; Ingerslev J
J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
[TBL] [Abstract][Full Text] [Related]
11. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
Croom KF; McCormack PL
BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
[TBL] [Abstract][Full Text] [Related]
13. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
Doshi BS; Gangadharan B; Doering CB; Meeks SL
PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
[TBL] [Abstract][Full Text] [Related]
15. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis.
Marta-Enguita J; Navarro-Oviedo M; Machado FJDM; Bermejo R; Aymerich N; Herrera M; Zandio B; Pagola J; Juega J; Marta-Moreno J; Rodriguez JA; Páramo JA; Roncal C; Muñoz R; Orbe J
J Thromb Haemost; 2024 Apr; 22(4):1080-1093. PubMed ID: 38160727
[TBL] [Abstract][Full Text] [Related]
16. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.
Siebenlist KR; Meh DA; Mosesson MW
Thromb Haemost; 2001 Nov; 86(5):1221-8. PubMed ID: 11816711
[TBL] [Abstract][Full Text] [Related]
17. Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice.
Kattula S; Byrnes JR; Martin SM; Holle LA; Cooley BC; Flick MJ; Wolberg AS
Blood Adv; 2018 Jan; 2(1):25-35. PubMed ID: 29344582
[TBL] [Abstract][Full Text] [Related]
18. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
Lisman T; de Groot PG; Lambert T; Røjkjaer R; Persson E
J Thromb Haemost; 2003 Oct; 1(10):2175-8. PubMed ID: 14521601
[TBL] [Abstract][Full Text] [Related]
19. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
20. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
Veldman A; Hoffman M; Ehrenforth S
Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
